Therapeutic Ultrasound in the Treatment of Migraine

Not Applicable

Completed

• Conditions: Migraine; Ultrasound
• Interventions: Device: therapeutic ultrasound; Device: placebo ultrasound

• Registration Number: NCT03459495
• Lead Sponsor: Bursa Yüksek İhtisas Education and Research Hospital

Brief Summary

Headache affects the daily quality of life of patients. It has been reported that headaches may be associated with neck muscles, neck movements and trigger points in the neck Drug and non-drug treatments can be used today in the treatment of headaches. Various physical therapies are applied to cranial and cervical regions in non-drug therapies. Therapeutic ultrasound, Transcutaneous Electrical Nerve Stimulation (TENS), Hotpack and manipulation are some of them.This is a randomised placebo- controlled trial to determine the efficacy of the therapeutic ultrasound in the treatment of migraine.

Detailed Description

Evidence from controlled studies suggests that non-invasive physical therapies may help prevent headaches. Therapeutic ultrasound studies have generally been used in combination with other physical therapies.

Therapeutic ultrasound is known to act in two different ways, thermal and non-thermal. With thermal effect, it is possible to reduce pain and joint joints and increase local blood flow, while stimulating tissue regeneration, soft tissue repair, blood flow regulation in chronic ischemic tissues and protein synthesis with nonthermal effect. In addition, its effect on inflammation accelerated repair by affecting cell activities, altering platelet membrane permeability, leading to the release of serotonin and accelerating wound healing.

The aim of this study is to determine whether therapeutic ultrasound is superior to placebo ultrasound in the treatment of migraine.

Study Timeline

• Study First Submitted: 2018-03-01
• Study First Submitted QC: 2018-03-07
• Study First Posted: 2018-03-09
• Study Start: 2018-03-10
• Primary Completion: 2018-09-10
• Study Completion: 2018-12-10
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-22
• Last Update Posted: 2019-07-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

• Patients between 20-65 years
• Patients diagnosed with migraine according to the International Headache Society (IHS) criteria

Exclusion Criteria

• Patients with bleeding disorders,
• Patients with mental disorders,
• Patients with malignancy,
• Patients with uncontrolled hypertension,
• Patients with uncontrolled diabetes mellitus,
• Patients with infection,
• Patients who underwent surgery in the posterior cranial region and cervical vertebra.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A	therapeutic ultrasound	Group A: ultrasound group
Group P	placebo ultrasound	Group P: placebo ultrasound group

Primary Outcome Measures

Name	Time	Method
Numeric rating scale (NRS)	4 months	It is commonly used to measure the severity of the patients' pain. It consists of a line 10 cm. long and marked with numbers from 0 to 10. The patient is asked to mark the point corresponding to the severity of the pain on this line in the range from 0 (no pain) to 10 (most severe pain).
Migraine Disability Assessment Questionnaire Score (MIDAS)	4 months	The Migraine Disability Assessment (MIDAS) questionnaire is a brief, self-administered questionnaire designed to quantify headache-related disability over a 3 month period. The MIDAS score is based on five disability questions in three dimensions: questions one and two assess the number of missed or significant limitations to activity (defined as at least 50% reduced productivity) days due to headache in school or paid work activities (school/job dimension); questions three and four assess the number of missed or significant limitations to activity (defined as at least 50% reduced productivity) days due to headache in housework activities (housework dimension); question five assesses missed days due to headache in family, social, or leisure activities (social dimension).; 0 to 5 - MIDAS Grade I, Little or no disability 6 to 10 - MIDAS Grade II, Mild disability 11 to 20 - MIDAS Grade III, Moderate disability 21+ - MIDAS Grade IV, Severe disability

Secondary Outcome Measures

Name	Time	Method
paracetamol consumption	4 months
the number of migraine attacks per month.	4 months

Trial Locations

Locations (1)

Burcu Metin Ökmen; 🇹🇷 Bursa, Turkey